mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Z Wang, F Schmidt, Y Weisblum, F Muecksch, CO Barnes, S Finkin, ... Nature 592 (7855), 616-622, 2021 | 1495 | 2021 |
Myc regulates chromatin decompaction and nuclear architecture during B cell activation KR Kieffer-Kwon, K Nimura, SSP Rao, J Xu, S Jung, A Pekowska, M Dose, ... Molecular cell 67 (4), 566-578. e10, 2017 | 196 | 2017 |
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants J Xu, K Xu, S Jung, A Conte, J Lieberman, F Muecksch, JCC Lorenzi, ... Nature 595 (7866), 278-282, 2021 | 191 | 2021 |
An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells L Wang, Y Shen, R Song, Y Sun, J Xu, Q Xu Molecular pharmacology 76 (6), 1238-1245, 2009 | 104 | 2009 |
Synthesis of a novel series of diphenolic chromone derivatives as inhibitors of NO production in LPS-activated RAW264. 7 macrophages GB Liu, JL Xu, M Geng, R Xu, RR Hui, JW Zhao, Q Xu, HX Xu, JX Li Bioorganic & medicinal chemistry 18 (8), 2864-2871, 2010 | 44 | 2010 |
VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C J Xu, S Cao, L Wang, R Xu, G Chen, Q Xu PloS one 6 (11), e27165, 2011 | 40 | 2011 |
APE1 is dispensable for S-region cleavage but required for its repair in class switch recombination J Xu, A Husain, W Hu, T Honjo, M Kobayashi Proceedings of the National Academy of Sciences 111 (48), 17242-17247, 2014 | 37 | 2014 |
C-terminal region of activation-induced cytidine deaminase (AID) is required for efficient class switch recombination and gene conversion S Sabouri, M Kobayashi, NA Begum, J Xu, K Hirota, T Honjo Proceedings of the National Academy of Sciences 111 (6), 2253-2258, 2014 | 32 | 2014 |
SAMHD 1‐mediated dNTP degradation is required for efficient DNA repair during antibody class switch recombination A Husain, J Xu, H Fujii, M Nakata, M Kobayashi, JY Wang, J Rehwinkel, ... The EMBO journal 39 (15), e102931, 2020 | 28 | 2020 |
Synthesis and evaluation of a novel series of quinoline derivatives with immunosuppressive activity GB Liu, JL Xu, CC He, G Chen, Q Xu, HX Xu, JX Li Bioorganic & medicinal chemistry 17 (15), 5433-5441, 2009 | 21 | 2009 |
A novel synthetic oleanolic acid derivative with amino acid conjugate suppresses tumour growth by inducing cell cycle arrest XM Lu, HW Yi, JL Xu, Y Sun, JX Li, SX Cao, Q Xu Journal of pharmacy and pharmacology 59 (8), 1087-1093, 2007 | 20 | 2007 |
Dregea volubilis Ameliorates Concanavalin A-Induced Liver Injury by Facilitating Apoptosis of Activated T Cells F Gong, Y Shen, C Zhang, J Xu, X Wu, Z Hua, Q Xu Experimental biology and medicine 233 (9), 1124-1132, 2008 | 15 | 2008 |
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. bioRxiv Z Wang, F Schmidt, Y Weisblum, F Muecksch, CO Barnes, S Finkin, ... Published online January 19, 2021 | 10 | 2021 |
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. bioRxiv. 2021 Z Wang, F Schmidt, Y Weisblum, F Muecksch, CO Barnes, S Finkin, ... CrossRef][PubMed], 2021 | 9 | 2021 |
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.[PMC free article][PubMed][CrossRef][Google Scholar] Z Wang, F Schmidt, Y Weisblum, F Muecksch, CO Barnes, S Finkin, ... | 4* | 2021 |
Activation-induced cytidine deaminase is dispensable for virus-mediated liver and skin tumor development in mouse models T Nguyen, J Xu, S Chikuma, H Hiai, K Kinoshita, K Moriya, K Koike, ... International immunology 26 (7), 397-406, 2014 | 4 | 2014 |
An anticancer effect of curcumin mediated by down-regulating PRL-3 expression on highly metastatic melanoma cells L Wang, Y Shen, R Song, Y Sun, J Xu, Q Xu Molecular Pharmacology, 2009 | 2 | 2009 |
Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1 J Xu, T Zhou, K McKee, B Zhang, C Liu, AF Nazzari, A Pegu, CH Shen, ... Advanced Science, 2309268, 2024 | | 2024 |
Tumor metastasis-associated molecule PRL-3: structure, function and possibility as the target of anti-cancer drugs J Xu, S Cao, Q Xu JOURNAL-CHINA PHARMACEUTICAL UNIVERSITY 39 (1), 001, 2008 | | 2008 |